Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""PROGNOSIS"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 12817
Tytuł:
Spatial transcriptomics reveals prognosis-associated cellular heterogeneity in the papillary thyroid carcinoma microenvironment.
Autorzy:
Yan K; Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Liu QZ; Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, China.
Huang RR; Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Jiang YH; Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, China.
Bian ZH; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, China.
Li SJ; Department of Thyroid Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Li L; Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Shen F; Department of Thyroid Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Tsuneyama K; Department of Pathology and Laboratory Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Zhang QL; Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Lian ZX; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Guan H; Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Xu B; Department of Thyroid Surgery, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2024 Mar; Vol. 14 (3), pp. e1594.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Thyroid Neoplasms*/diagnosis
Thyroid Neoplasms*/genetics
Thyroid Neoplasms*/metabolism
Humans ; Thyroid Cancer, Papillary/genetics ; Thyroid Cancer, Papillary/metabolism ; Thyroid Cancer, Papillary/pathology ; Ligands ; Tumor Microenvironment/genetics ; Neoplasm Recurrence, Local ; Gene Expression Profiling ; Prognosis ; RNA
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.
Autorzy:
Mendiburu-Eliçabe M; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.
García-Sancha N; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Corchado-Cobos R; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Martínez-López A; Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas, Universidad Complutense, Madrid, Spain.; San Carlos Health Research Institute (IdISSC), Madrid, Spain.
Chang H; Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory (LBNL), Berkeley, California, USA.; Berkeley Biomedical Data Science Center, Lawrence Berkeley National Laboratory (LBNL), Berkeley, California, USA.
Hua Mao J; Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory (LBNL), Berkeley, California, USA.; Berkeley Biomedical Data Science Center, Lawrence Berkeley National Laboratory (LBNL), Berkeley, California, USA.
Blanco-Gómez A; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.
García-Casas A; Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas, Universidad Complutense, Madrid, Spain.; San Carlos Health Research Institute (IdISSC), Madrid, Spain.
Castellanos-Martín A; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Salvador N; Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas, Universidad Complutense, Madrid, Spain.; San Carlos Health Research Institute (IdISSC), Madrid, Spain.
Jiménez-Navas A; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Pérez-Baena MJ; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Sánchez-Martín MA; Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.; Servicio de Transgénesis, Plataforma Nucleus, Universidad de Salamanca, Salamanca, Spain.
Abad-Hernández MDM; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain.; Servicio de Anatomía Patológica, Hospital Universitario de Salamanca, Salamanca, Spain.
Carmen SD; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain.; Servicio de Anatomía Patológica, Hospital Universitario de Salamanca, Salamanca, Spain.
Claros-Ampuero J; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.; Servicio de Oncología, Hospital Universitario de Salamanca, Salamanca, Spain.
Cruz-Hernández JJ; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.; Servicio de Oncología, Hospital Universitario de Salamanca, Salamanca, Spain.
Rodríguez-Sánchez CA; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.; Servicio de Oncología, Hospital Universitario de Salamanca, Salamanca, Spain.
García-Cenador MB; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.
García-Criado FJ; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.
Vicente RS; Departamento de Informática y Automática, Universidad de Salamanca, Salamanca, España.
Castillo-Lluva S; Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas, Universidad Complutense, Madrid, Spain.; San Carlos Health Research Institute (IdISSC), Madrid, Spain.
Pérez-Losada J; Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.; Biosanitary Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2024 Feb; Vol. 14 (2), pp. e1554.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Humans ; Mice ; Animals ; Female ; Neoplasm Recurrence, Local/genetics ; Gene Expression Profiling ; Prognosis ; Mice, Transgenic ; Nuclear Proteins/genetics ; Cell Cycle Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Autorzy:
Chen Y; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.; Department of Molecular Biosciences and Bioengineering, College of Tropical Agriculture and Human Resources, Agricultural Sciences, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Gao Z; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.; Department of Molecular Biosciences and Bioengineering, College of Tropical Agriculture and Human Resources, Agricultural Sciences, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Mohd-Ibrahim I; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.; Department of Molecular Biosciences and Bioengineering, College of Tropical Agriculture and Human Resources, Agricultural Sciences, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Yang H; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Wu L; Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Fu Y; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Deng Y; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2024 Feb; Vol. 14 (2), pp. e1543.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Bromodomain Containing Proteins*
Transcription Factors*/genetics
Transcription Factors*/metabolism
Neoplasms*/diagnosis
Neoplasms*/genetics
Humans ; Chromatin ; Chromosomal Proteins, Non-Histone/genetics ; Colonic Neoplasms ; Melanoma/diagnosis ; Melanoma/drug therapy ; Melanoma/genetics ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Autorzy:
Wang Y; Department of Orthopaedic Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, P. R. China.; Institute of Bone Tumor Affiliated to Tongji University School of Medicine, Shanghai, P. R. China.; Proteomics and Cancer Cell Signaling Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ma X; Department of Orthopaedic Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, P. R. China.; Institute of Bone Tumor Affiliated to Tongji University School of Medicine, Shanghai, P. R. China.
Xu E; Department of Orthopaedic Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, P. R. China.; Institute of Bone Tumor Affiliated to Tongji University School of Medicine, Shanghai, P. R. China.
Huang Z; Department of Orthopaedic Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, P. R. China.; Institute of Bone Tumor Affiliated to Tongji University School of Medicine, Shanghai, P. R. China.
Yang C; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
Zhu K; Department of Orthopaedic Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, P. R. China.; Institute of Bone Tumor Affiliated to Tongji University School of Medicine, Shanghai, P. R. China.
Dong Y; Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China.
Zhang C; Department of Orthopaedic Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, P. R. China.; Institute of Bone Tumor Affiliated to Tongji University School of Medicine, Shanghai, P. R. China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2024 Feb; Vol. 14 (2), pp. e1586.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Bone Neoplasms*
Osteosarcoma*/drug therapy
Osteosarcoma*/genetics
Squalene Monooxygenase*/genetics
Squalene Monooxygenase*/metabolism
Humans ; Artificial Intelligence ; Biomarkers ; Phosphatidylinositol 3-Kinases ; Prognosis ; Proto-Oncogene Proteins c-akt
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tumorigenicity and prediction of clinical prognosis of patient-derived gastric cancer organoids.
Autorzy:
Wang T; The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Song W; The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Meng Q; Department of General Surgery, The First Medical Center, PLA General Hospital, Beijing, China.
Qu C; The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Guo S; Department of General Surgery, The First Medical Center, PLA General Hospital, Beijing, China.
Wang Y; Guangzhou National Laboratory, Guangzhou, China.
Tan R; Guangzhou National Laboratory, Guangzhou, China.
Jia B; Department of General Surgery, The First Medical Center, PLA General Hospital, Beijing, China.
Chen YG; The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.; Guangzhou National Laboratory, Guangzhou, China.; School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2024 Feb; Vol. 14 (2), pp. e1588.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Stomach Neoplasms*/diagnosis
Humans ; Organoids ; Prognosis
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy prediction.
Autorzy:
Ge Q; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.; Institute of Urology, Anhui Medical University, Hefei, P. R. China.; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, P. R. China.
Zhao Z; Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
Li X; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.; Institute of Urology, Anhui Medical University, Hefei, P. R. China.; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, P. R. China.
Yang F; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.; Institute of Urology, Anhui Medical University, Hefei, P. R. China.; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, P. R. China.
Zhang M; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.; Institute of Urology, Anhui Medical University, Hefei, P. R. China.; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, P. R. China.
Hao Z; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.; Institute of Urology, Anhui Medical University, Hefei, P. R. China.; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, P. R. China.
Liang C; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.; Institute of Urology, Anhui Medical University, Hefei, P. R. China.; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, P. R. China.; Anhui Provincial Institute of Translational Medicine, Hefei, P. R. China.
Meng J; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.; Institute of Urology, Anhui Medical University, Hefei, P. R. China.; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, P. R. China.; Anhui Provincial Institute of Translational Medicine, Hefei, P. R. China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2024 Jan; Vol. 14 (1), pp. e1552.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
T-Lymphocytes, Regulatory*
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/therapy
Male ; Humans ; Prognosis ; Tumor Microenvironment
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A multistate platform model for time-to-event endpoints in oncology clinical trials.
Autorzy:
Lin CW; Clinical Pharmacology Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
Nagase M; Clinical Pharmacology Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
Doshi S; Clinical Pharmacology Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
Dutta S; Clinical Pharmacology Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jan; Vol. 13 (1), pp. 154-167. Date of Electronic Publication: 2023 Nov 08.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms*/drug therapy
Humans ; Prognosis ; Progression-Free Survival ; Medical Oncology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Performance of established disease severity scores in predicting severe outcomes among adults hospitalized with influenza-FluSurv-NET, 2017-2018.
Autorzy:
Doyle JD; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC Atlanta Georgia USA.; Epidemic Intelligence Service, CDC Atlanta Georgia USA.
Garg S; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC Atlanta Georgia USA.
O'Halloran AC; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC Atlanta Georgia USA.
Grant L; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC Atlanta Georgia USA.
Anderson EJ; Emory University School of Medicine Atlanta Georgia USA.; Atlanta Veterans Affairs Medical Center Atlanta Georgia USA.
Openo KP; Emory University School of Medicine Atlanta Georgia USA.; Atlanta Veterans Affairs Medical Center Atlanta Georgia USA.; Georgia Emerging Infections Program, Georgia Department of Health Atlanta Georgia USA.
Alden NB; Colorado Department of Public Health and Environment Denver Colorado USA.
Herlihy R; Colorado Department of Public Health and Environment Denver Colorado USA.
Meek J; Connecticut Emerging Infections Program Yale School of Public Health New Haven Connecticut USA.
Yousey-Hindes K; Connecticut Emerging Infections Program Yale School of Public Health New Haven Connecticut USA.
Monroe ML; Maryland Department of Health Baltimore Maryland USA.
Kim S; Communicable Disease Division, Michigan Department of Health and Human Services Lansing Michigan USA.
Lynfield R; Minnesota Department of Health Saint Paul Minnesota USA.
McMahon M; Minnesota Department of Health Saint Paul Minnesota USA.
Muse A; New York State Department of Health Albany New York USA.
Spina N; New York State Department of Health Albany New York USA.
Irizarry L; New Mexico Department of Health Albuquerque New Mexico USA.
Torres S; New Mexico Department of Health Albuquerque New Mexico USA.
Bennett NM; University of Rochester School of Medicine and Dentistry Rochester New York USA.
Gaitan MA; University of Rochester School of Medicine and Dentistry Rochester New York USA.
Hill M; Salt Lake County Health Department Salt Lake City Utah USA.
Cummings CN; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC Atlanta Georgia USA.
Reed C; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC Atlanta Georgia USA.
Schaffner W; Vanderbilt University School of Medicine Nashville Tennessee USA.
Talbot HK; Vanderbilt University School of Medicine Nashville Tennessee USA.
Self WH; Vanderbilt University School of Medicine Nashville Tennessee USA.
Williams D; Vanderbilt University School of Medicine Nashville Tennessee USA.
Pokaż więcej
Źródło:
Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2023 Dec 17; Vol. 17 (12), pp. e13228. Date of Electronic Publication: 2023 Dec 17 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Influenza, Human*/diagnosis
Influenza, Human*/epidemiology
Pneumonia*
Adult ; Humans ; Severity of Illness Index ; Hospitalization ; Patient Acuity ; ROC Curve ; Prognosis ; Retrospective Studies ; Intensive Care Units
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab.
Autorzy:
Zhang N; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Chan ML; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Li J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA.
Brohawn PZ; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceutical R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Sun B; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA.
Vainshtein I; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA.
Roskos LK; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA.
Faggioni R; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA.
Savic RM; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1945-1959. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Crohn Disease*/drug therapy
Humans ; ATP Binding Cassette Transporter, Subfamily G, Member 2 ; Prognosis ; Remission Induction ; Neoplasm Proteins/metabolism ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Biomarkers/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status.
Autorzy:
Gamrani S; Medical Center of Biomedical and Translational Research, Hassan II University Hospital, Faculty of Medicine and Pharmacy, University Sidi Mohamed Ben Abdellah, Fez, Morocco.; Laboratory of Anatomic Pathology and Molecular Pathology, University Hospital Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
Akhouayri L; Dipartimento di Scienze Cliniche e Biologiche, Università Degli Studi Di Torino, Via Giuseppe Verdi, Torino, Italy.; Department of Biomedical Sciences, Genetics and Molecular Biology Laboratory, Faculty of Medicine and Pharmacy, Hassan II-Casablanca University, Rue Tariq Ibn Ziad, Casablanca, Morocco.
Boukansa S; Medical Center of Biomedical and Translational Research, Hassan II University Hospital, Faculty of Medicine and Pharmacy, University Sidi Mohamed Ben Abdellah, Fez, Morocco.; Laboratory of Anatomic Pathology and Molecular Pathology, University Hospital Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
Karkouri M; Department of Biomedical Sciences, Genetics and Molecular Biology Laboratory, Faculty of Medicine and Pharmacy, Hassan II-Casablanca University, Rue Tariq Ibn Ziad, Casablanca, Morocco.; Department of Pathology, Ibn Rochd University Hospital, Rue des Hôpitaux, Casablanca, Morocco.
El Fatemi H; Medical Center of Biomedical and Translational Research, Hassan II University Hospital, Faculty of Medicine and Pharmacy, University Sidi Mohamed Ben Abdellah, Fez, Morocco.; Laboratory of Anatomic Pathology and Molecular Pathology, University Hospital Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2023 Nov 30; Vol. 2023, pp. 6621409. Date of Electronic Publication: 2023 Nov 30 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Humans ; Female ; Prognosis ; Biomarkers, Tumor/analysis ; Receptor, ErbB-2/analysis ; Retrospective Studies ; In Situ Hybridization, Fluorescence ; Receptors, Progesterone
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.
Autorzy:
Shao HY; Department of CT/MR, Xingtai People's Hospital, Xingtai, Hebei, China.
Hao BT; Department of Thoracic Surgery, Xingtai People's Hospital, Xingtai, Hebei, China.
Gao FX; Department of CT/MR, Xingtai People's Hospital, Xingtai, Hebei, China.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2023 Nov 11; Vol. 2023, pp. 7028189. Date of Electronic Publication: 2023 Nov 11 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Lung Neoplasms*/epidemiology
Humans ; Female ; Male ; Biomarkers, Tumor/metabolism ; Receptors, Estrogen/metabolism ; Retrospective Studies ; Receptors, Progesterone/metabolism ; Receptor, ErbB-2/metabolism ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
LEPRE1 shapes a non-flamed tumour immune landscape and predicts the prognosis in esophageal squamous cell carcinoma.
Autorzy:
Liu M; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.; The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang,Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Ma Y; Department of Clinical Laboratory, The Fourth People' Hospital of Urumqi, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Guo Y; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Ma Y; Department of Pharmacy, Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Bao X; Department of Pharmacy, Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Lu X; Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Nov; Vol. 13 (11), pp. e1473.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Esophageal Squamous Cell Carcinoma*
Esophageal Neoplasms*/diagnosis
Esophageal Neoplasms*/pathology
Carcinoma, Squamous Cell*/diagnosis
Carcinoma, Squamous Cell*/pathology
Humans ; Prognosis
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Autorzy:
Ojara FW; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.; Graduate Research Training Program PharMetrX, Berlin/Potsdam, Germany.
Henrich A; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.; Graduate Research Training Program PharMetrX, Berlin/Potsdam, Germany.
Frances N; Department of Translational Modeling and Simulation, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Nassar YM; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.; Graduate Research Training Program PharMetrX, Berlin/Potsdam, Germany.
Huisinga W; Institute of Mathematics, University of Potsdam, Potsdam, Germany.
Hartung N; Institute of Mathematics, University of Potsdam, Potsdam, Germany.
Geiger K; Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Center, Technical University of Munich, Munich, Germany.
Holdenrieder S; Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Center, Technical University of Munich, Munich, Germany.
Joerger M; Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Kloft C; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Nov; Vol. 12 (11), pp. 1714-1725. Date of Electronic Publication: 2023 Feb 27.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*/pathology
Humans ; Paclitaxel ; Prognosis ; Platinum/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
TIMP1 is an early biomarker for detection and prognosis of lung cancer.
Autorzy:
Dantas E; Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
Murthy A; Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
Ahmed T; Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
Ahmed M; Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
Ramsamooj S; Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
Hurd MA; Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
Lam T; Weill Cornell Medical College, Weill Cornell Medicine, New York, New York, USA.
Malbari M; Division of Thoracic Surgery, Weill Cornell Medicine, New York, New York, USA.
Agrusa C; Weill Cornell Medical College, Weill Cornell Medicine, New York, New York, USA.
Elemento O; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.; Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA.; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, USA.
Zhang C; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
Pappin DJ; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.
McGraw TE; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.; Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA.; Department of Biochemistry, Weill Cornell Medicine, New York, New York, USA.
Stiles BM; Department of Cardiothoracic and Vascular Surgery, Albert Einstein College of Medicine, Bronx, New York, USA.
Altorki NK; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.; Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA.
Goncalves MD; Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.; Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Oct; Vol. 13 (10), pp. e1391.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Tissue Inhibitor of Metalloproteinase-1*/genetics
Lung Neoplasms*/diagnosis
Lung Neoplasms*/genetics
Humans ; Animals ; Mice ; Proteomics ; Prognosis ; Biomarkers ; Neoplasm Proteins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
LILRB3 suppresses immunity in glioma and is associated with poor prognosis.
Autorzy:
Zhuang Q; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Liu Y; Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, P. R. China.
Wang H; Institute for Translational Brain Research, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Lin Z; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Sun L; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Liu Y; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Lyu Y; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Chen L; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.; National Center for Neurological Disorders, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, P. R. China.; Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai Clinical Medical Center of Neurosurgery, Neurosurgical Institute of Fudan University, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, P. R. China.; State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Yang H; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.; Institute for Translational Brain Research, Shanghai Medical College, Fudan University, Shanghai, P. R. China.; National Center for Neurological Disorders, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, P. R. China.; Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai Clinical Medical Center of Neurosurgery, Neurosurgical Institute of Fudan University, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, P. R. China.; State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Mao Y; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.; National Center for Neurological Disorders, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, P. R. China.; Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai Clinical Medical Center of Neurosurgery, Neurosurgical Institute of Fudan University, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, P. R. China.; State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, P. R. China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Oct; Vol. 13 (10), pp. e1396.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioma*/genetics
Brain Neoplasms*/genetics
Humans ; Prognosis ; Receptors, Immunologic ; Antigens, CD
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identification and validation of GABA-driven subtypes and prognosis signature of lung adenocarcinoma.
Autorzy:
Li L; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Medical school, Huanghe Science and Technology University, Zhengzhou, Henan, China.
Sun S; National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Peng M; Department of Clinical Laboratory, Henan No. 3 Provincial People's Hospital, Zhengzhou, Henan, China.
Wu K; Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Duan X; National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xue R; National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yang M; National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang X; National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhao J; National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Oct; Vol. 13 (10), pp. e1450.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma of Lung*/diagnosis
Lung Neoplasms*/diagnosis
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Prognosis ; gamma-Aminobutyric Acid
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Benign Phyllodes Tumors: Comparison of Prognosis among Three Different Surgical Approaches.
Autorzy:
Jiang Y; School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.
Wang B; Department of Ultrasound, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.
Li JK; Department of Ultrasound, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.
Li SY; Department of Ultrasound, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.
Niu RL; Department of Ultrasound, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.
Fu NQ; Department of Ultrasound, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.
Zheng JJ; Department of Ultrasound, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.
Liu G; Department of Radiology, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.
Wang ZL; School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.; Department of Ultrasound, Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Beijing 100853, China.
Pokaż więcej
Źródło:
The breast journal [Breast J] 2023 Sep 20; Vol. 2023, pp. 1682084. Date of Electronic Publication: 2023 Sep 20 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/surgery
Breast Neoplasms*/pathology
Phyllodes Tumor*/surgery
Phyllodes Tumor*/pathology
Humans ; Female ; Margins of Excision ; Retrospective Studies ; Neoplasm Recurrence, Local/pathology ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers.
Autorzy:
Liu Y; State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhang Y; CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xie W; Burning Rock Biotech, Guangdong, China.
Zhao J; Burning Rock Biotech, Guangdong, China.
Dong Y; CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xu C; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Zhejiang, China.
Wang Y; Burning Rock Biotech, Guangdong, China.
Li M; CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wang G; Burning Rock Biotech, Guangdong, China.
Zhu X; Burning Rock Biotech, Guangdong, China.
Wang W; Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Zhejiang, China.
Lin K; Burning Rock Biotech, Guangdong, China.
Lu H; Burning Rock Biotech, Guangdong, China.
Han Y; Burning Rock Biotech, Guangdong, China.
Li L; Burning Rock Biotech, Guangdong, China.
Duan J; CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Cai S; Burning Rock Biotech, Guangdong, China.
Wang J; CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wang Z; CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Sep; Vol. 13 (9), pp. e1354.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/diagnosis
Neoplasms*/therapy
Humans ; Prognosis ; Immunotherapy ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy.
Autorzy:
Wang Q; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Sun K; State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, China.; Yunnan Key Laboratory of Primate Biomedical Research, Kunming, China.
Liu R; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Song Y; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Lv Y; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Bi P; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Yang F; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Li S; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Zhao J; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Li X; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Chen D; Department of Ultrasound, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Mei J; Department of Cardiothoracic Surgery, Baoshan People's Hospital, Baoshan, China.
Yang R; Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.; Department of Immunology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, China.
Chen K; State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, China.; Yunnan Key Laboratory of Primate Biomedical Research, Kunming, China.
Liu D; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Tang S; Department of Breast Surgery, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Aug; Vol. 13 (8), pp. e1346.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*/diagnosis
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Tertiary Lymphoid Structures*/genetics
Tertiary Lymphoid Structures*/metabolism
Humans ; Female ; Transcriptome/genetics ; Neoadjuvant Therapy ; Lymphocytes, Tumor-Infiltrating ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery.
Autorzy:
Sun L; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China.; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China.; Colorectal Institute of Nanjing Medical University, Nanjing, China.
Ke X; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China.
Guan A; Eight-year MD Program, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences, Beijing, China.
Jin B; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China.
Qu J; Eight-year MD Program, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences, Beijing, China.
Wang Y; Eight-year MD Program, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences, Beijing, China.
Xu X; Eight-year MD Program, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences, Beijing, China.
Li C; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China.
Sun H; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China.
Xu H; Eight-year MD Program, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences, Beijing, China.
Xu G; Liver Transplant Center, Organ Transplant Center, West China Hospital of Sichuan University, Chengdu, China.; Laboratory of Liver Transplantation, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital of Sichuan University, Chengdu, China.
Sang X; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China.
Feng Y; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China.; Colorectal Institute of Nanjing Medical University, Nanjing, China.
Sun Y; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China.; Colorectal Institute of Nanjing Medical University, Nanjing, China.
Yang H; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China.
Mao Y; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Jul; Vol. 13 (7), pp. e1331.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/diagnosis
Carcinoma, Hepatocellular*/surgery
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/genetics
Microbiota*/genetics
Humans ; Prognosis ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 12817

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies